Stockwinners Market Radar for August 11, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:10 EDT Cathie Wood's ARK Investment bought 628K shares of Fate Therapeutics today

18:48 EDT T-Mobile exec sells $7.26M in common stock - In a regulatory filing, T-Mobile disclosed that its Technology President Nevilled Ray sold 50K shares of common stock on August 9th in a total transaction size of $7.26M.

18:35 EDT Agios announces publication of Phase 2 PYRUKYND data in The Lancet - Agios Pharmaceuticals announced that data from the core period of the open-label, Phase 2 study of PYRUKYND in adults with non-transfusion-dependent alpha- or beta-thalassemia were published on August 11, 2022, in The Lancet. Data from this study were previously presented at the 2021 European Hematology Association Annual Congress. PYRUKYND is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase enzymes. "Consistent with previously reported findings, the data reported today underscore the potential of PK activation to improve hallmarks of alpha- and beta-thalassemia, including hemolysis and ineffective erythropoiesis," said Kevin Kuo, M.D., hematologist at University of Toronto, Toronto General Hospital, and an investigator in the study. "Thalassemia is a rare, debilitating lifelong blood disorder characterized by severe complications, with no treatment options for those with alpha-thalassemia and limited options for those with beta-thalassemia. These data demonstrate the potential clinical benefits of mitapivat for a broad spectrum of thalassemia patients and support its continued investigation in pivotal trials."

18:19 EDT Quanterix director buys $100K in common stock - In a regulatory filing, Quanterix director Sarah Hlavinka disclosed the purchase of 10.1K common shares of the company on August 11 at a price of $9.89 per share. Shares of Quanterix rose 18.7% today following insider buying activity yesterday evening and are up another 6.2% afterhours.

18:01 EDT Teens are leaving Facebook, YouTube used by 95% of teens, Pew Research says - "The landscape of social media is ever-changing, especially among teens who often are on the leading edge of this space. A new Pew Research Center survey of American teenagers ages 13 to 17 finds TikTok has rocketed in popularity since its North American debut several years ago and now is a top social media platform for teens among the platforms covered in this survey. Some 67% of teens say they ever use TikTok, with 16% of all teens saying they use it almost constantly. Meanwhile, the share of teens who say they use Facebook, a dominant social media platform among teens in the Center's 2014-15 survey, has plummeted from 71% then to 32% today. YouTube (GOOG) tops the 2022 teen online landscape among the platforms covered in the Center's new survey, as it is used by 95% of teens. TikTok is next on the list of platforms that were asked about in this survey,67%, followed by Instagram and Snapchat (SNAP), which are both used by about six-in-ten teens. After those platforms come Facebook (META) with 32% and smaller shares who use Twitter (TWTR), Twitch, WhatsApp, Reddit and Tumblr,"wrote Emily Vogels, Risa Gelles-Watnick and Navid Massarat for Pew Research. Reference Link

17:33 EDT Johnson & Johnson to discontinue talc-based Baby Powder in 2023 - "As part of a worldwide portfolio assessment, we have made the commercial decision to transition to an all cornstarch-based baby powder portfolio. As a result of this transition, talc-based JOHNSON'S Baby Powder will be discontinued globally in 2023. We continuously evaluate and optimize our portfolio to best position the business for long-term growth. This transition will help simplify our product offerings, deliver sustainable innovation, and meet the needs of our consumers, customers and evolving global trends. Cornstarch-based JOHNSON'S(R) Baby Powder is already sold in countries around the world. JOHNSON'S is a flagship global brand of Johnson & Johnson Consumer Health and we remain fully committed to ensuring JOHNSON'S products are loved by parents and families for years to come. Our position on the safety of our cosmetic talc remains unchanged. We stand firmly behind the decades of independent scientific analysis by medical experts around the world that confirms talc-based JOHNSON'S(R) Baby Powder is safe, does not contain asbestos, and does not cause cancer." Reference Link

17:27 EDT Rivian Automotive cuts FY22 adjusted EBITDA target to loss of $5.45B from $4.75B - Still sees FY22 production of 25,000 vehicles. Says lowering FY22 capital expenditures target to $2B from $2.6B. Sees FY22 cash position in line with initial expectations. Says lithium price increased over 115% since beginning of the year. Sees clear path to gross margin and free cash flow targets. Sees room to raise prices. Says still experiencing supply chain constraints. Says Inflation Reduction Act will create needed tailwinds for both consumers and industry. Says supply chain constraints caused the need for expedited shipping. Says remains confident in ability to meet targets. Comments taken from Q2 earnings conference call.

17:26 EDT Telus and LifeWorks get regulatory approvals for proposed acquisition - Telus and LifeWorks announced that the Ontario Superior Court of Justice has granted its final order approving the plan of arrangement in respect of the acquisition by TELUS of LifeWorks previously announced on June 16., Telus and LifeWorks also announced that the Competition Bureau of Canada has issued a no action letter in respect of the Arrangement. Accordingly, Competition Act Approval, as defined and as required by the Arrangement Agreement previously entered into between LifeWorks and TELUS, has been obtained. In addition, the applicable waiting period in relation to the Arrangement under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired , with the result that the acquisition is clear to proceed in the United States as well as Canada. The Court Approval, the Competition Act Approval and the HSR Approval are significant milestones toward closing Telus ' acquisition of LifeWorks and follows LifeWorks' shareholder approval, which was obtained at a special meeting of LifeWorks' shareholders on August 4, 2022. Pending receipt of regulatory approvals in the United Kingdom and Australia, and the satisfaction of customary closing conditions, the Arrangement is expected to proceed to closing which is anticipated to be on or about the fourth quarter of 2022.

17:24 EDT Medifast director buys $498.5K in common stock - In a regulatory filing, Medifast disclosed that its director Jeffrey Brown bought 3.9K shares of common stock on August 9th in a total transaction size of $498.5K.

17:03 EDT IO Biotech reports Q2 EPS (64c), consensus (68c) - Cash and cash equivalents at June 30 were $170.1M, compared to $211.5M at December 31, 2021. Cash on hand is expected to support operations through anticipated data readouts into mid-2024. "We continue to advance our promising pipeline of novel cancer immunotherapies following clinical trial milestones achieved in the first half of the year," said Mai-Britt Zocca, president and CEO of IO Biotech. "During the quarter we were pleased to announce the initiation and dosing of first patients our Phase 3 global combination trial of IOB102-103 with pembrolizumab as a potential first line treatment in advanced melanoma. We look forward to enrolling patients across the U.S., Australia and Europe. We will provide an update on the anticipated timing of the interim data once we have sufficient information. During the quarter, we also announced the initiation and dosing of the first patient in our Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab. We expect to receive preliminary data in one indication in the second half of 2022, and additional data in 2023."

16:51 EDT Dorman Products announces release of 300 new auto parts - Dorman Products announced the release of 300 new auto parts, a third of which are aftermarket-exclusives. The new products join an expansive catalog of more than 118,000 aftermarket solutions that advance the company's mission of giving repair professionals and owners greater freedom to fix a wide range of passenger and commercial vehicles.

16:46 EDT Toast up 9% to $19.80 after smaller than expected Q2 loss, raised guidance

16:42 EDT Teekay Corp. announces $30M share repurchase program - Teekay Corp. announced that its board of directors has authorized a share repurchase program for the repurchase of up to $30M of the company's outstanding common shares. Under the program, repurchases can be made from time to time in the open market, through privately-negotiated transactions and by any other means permitted under the rules of the U.S. Securities and Exchange Commission, in each case at times and prices considered appropriate by the company.

16:35 EDT Churchill Downs to sell 49% of United Tote to NYRA - Churchill Downs announced that the company has entered into an agreement to sell 49% of United Tote, a wholly-owned subsidiary of CDI, to NYRA Content Management Solutions, a subsidiary of the New York Racing Association, or NYRA. NYRA is a not-for-profit corporation that operates the three largest Thoroughbred horse racing tracks in the state of New York - Aqueduct Racetrack in South Ozone Park, Queens; Belmont Park in Elmont; and Saratoga Race Course in Saratoga Springs. The transaction is subject to usual and customary closing conditions, including applicable regulatory notices and approvals, and is expected to close by the end of 2022. As part of the agreement, the United Tote pari-mutuel settlements business will be excluded and will remain with CDI. CDI and NYRA intend to work together to create and provide a pari-mutuel solution through United Tote that will expedite the expansion of horse racing onto sports wagering platforms to reach new customers. Pending the appropriate regulatory approvals, NYRA will transition its pari-mutuel wager processing to United Tote in 2023 under a separate agreement.

16:31 EDT Eagle Point Income increases monthly common distribution 12% to 14c per share - Eagle Point Income announce the declaration of distributions on shares of the Company's common stock. The Company has declared three separate distributions of $0.14 per share on its common stock, an increase of 12% from its previous monthly distribution of $0.125 per share, payable on each of October 31, 2022, November 30, 2022 and December 30, 2022 to stockholders of record as of October 11, 2022, November 10, 2022 and December 12, 2022, respectively. "Given the continued increase in interest rates, we are very pleased to increase our monthly common distribution by 12% to $0.14 per common share," said Thomas Majewski, Chairman and Chief Executive Officer.

16:29 EDT Savara expects cash to fund operations through 2025 - As of June 30, 2022, Savara had cash, cash equivalents, and short-term investments of approximately $142 million and debt of approximately $26 million.

16:26 EDT Illumina cuts FY22 core Illumina revenue growth view to 3.5%-4.5% - GRAIL revenue is now expected to be in the range of $50M-$70M. Prior view was Core Illumina revenue growth in the range of 13%-15%; GRAIL revenue in the range of $70M-$90M. Revision primarily reflects the ongoing negative impact of foreign exchange rates, customer lab expansion delays, and macroeconomic-driven conservatism around immediate capital and inventory commitments, including in Greater China.

16:24 EDT Rockley Photonics sees FY22 core product revenue $5M-$10M

16:23 EDT Voxeljet enters into sale-leaseback transaction for German facility - voxeljet AG "announced it has entered into a sale-leaseback arrangement expected to generate approximately EUR 26.5 million in gross proceeds. The Company plans to use the proceeds from this transaction to repay its financial liabilities. The transaction is expected to close towards the end of the third quarter 2022. The sale-leaseback transaction involving the Company's 135,380 square foot facility in Friedberg, Germany, was entered into with an institutional, unaffiliated real estate investor, and is subject to regulatory approvals in the Federal Republic of Germany. The leaseback of the facility provides for a fifteen-year lease commitment with two consecutive five-year extension option periods."

16:22 EDT SmartRent falls 28% to $4.02 after Q2 earnings miss and guidance cut

16:21 EDT ESS Inc. announces partnership to deploy long-term energy storage in Australia - ESS Inc. announced a strategic partnership with Energy Storage Industries Asia Pacific to distribute and manufacture iron flow batteries utilizing ESS technology in Australia, New Zealand and Oceania to meet rapidly growing demand for long-duration energy storage in the region. Under the terms of the agreement, ESS will initially supply 70 complete 75kW / 500kWh Energy Warehouse (EW) systems to ESI in 2022 and 2023. Concurrently, ESI will construct a manufacturing facility in Queensland, Australia, equipped to conduct final assembly of ESS systems from 2024 onward. Systems manufactured at the Queensland facility will utilize "core component kits" supplied by ESS including battery modules, proton pumps, and other unique components. Core component kits will continue to be manufactured in Wilsonville, Ore. The ESI manufacturing facility is designed to reach a production capacity of up to 400 MW of energy storage annually. "We look forward to deploying ESS technology in Australia and the region to meet the needs of energy customers and build a sustainable, resilient energy future," said Eric Dresselhuys, CEO of ESS. "ESI brings a wealth of experience and expertise in clean energy and energy storage and a keen understanding of the Australian energy market. We look forward to working with them to advance our shared mission to accelerate the clean energy transition by deploying long-duration energy storage solutions in the region."

16:18 EDT Core Scientific sees FY22 total hashrate 30-32 EH/s - For 2022, the company continues to expect to achieve total hashrate of between 30 EH/s and 32 EH/s, with total power of approximately 1 GW.

16:17 EDT Rivian Automotive reports Q2 output of 4.40K and deliveries of 4.47K vehicles

16:15 EDT Rivian Automotive affirms 2022 production target of 25K vehicles

16:12 EDT Graphite Bio expects cash to fund operations into Q4 of 2024 - As of June 30, 2022, cash, cash equivalents and investments in marketable securities totaled $328.3 million. The company continues to expect this will fund its planned operations into the fourth quarter of 2024.

16:07 EDT Kinder Morgan closes $135M deal for North American Natural Resources - Kinder Morgan "announced it has closed on the acquisition of North American Natural Resources, Inc. and its sister companies, North American Biofuels, LLC and North American-Central, LLC. The $135 million acquisition in combined purchase price and related transaction costs includes seven landfill gas-to-power facilities in Michigan and Kentucky. KMI expects the investment to be accretive to its shareholders as the four converted RNG facilities become operational over the next 18 months, with the purchase price and additional development capital expenditures representing less than six times the expected 2024 EBITDA."

16:04 EDT Chicken Soup for the Soul reports Q2 adjusted EBITDA $5.6M vs. $3.2M y/y

15:41 EDT Genentech says FDA approves sNDA for Xofluza - Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for Xofluza for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. This marks the first single-dose oral influenza medicine approved for children in this age group. Additionally, the FDA approved Xofluza for the prevention of influenza in children aged five to less than 12 years of age following contact with someone with influenza. "Despite the ongoing COVID-19 pandemic, influenza continues to be a threat to public health, and effective influenza antivirals remain critical to alleviating the burden on healthcare systems," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "Xofluza has proven to be an important tool in fighting and preventing influenza in adults as well as adolescents, and we are pleased to now offer households and younger children our single-dose oral treatment."

14:34 EDT Vuzix receives follow-on order for additional pre-production units - Vuzix announced it has received a follow-on six-figure order for additional pre-production units from a global Tier-1 aerospace and defense firm for their customized avionics waveguide-based head mounted display, HMD, system. The customized HMD waveguide and HD display engine development program with this customer continues to expand and move toward production. Vuzix has completed multiple stages of product development and refinement with this partner and is getting very close to meeting the customer's requirements for production roll-out. "On the heels of last week's L3Harris announcement, this follow-on order demonstrates that Vuzix is continuing to move forward with several other large aerospace and defense players, in this particular case as they finalize their solution and pursue multiple production opportunities," said Paul Travers, President and CEO of Vuzix. "OEM custom waveguide-based projects such as this represent a profitable vehicle for leveraging our extensive optical expertise and IP as well as our US production facilities. We look forward to announcing further developments with this firm, as well as numerous other programs around Vuzix growing OEM business."

13:53 EDT FDA grants regular approval to Novartis' capmatinib for metastatic NSCLC - On August 10, The FDA granted regular approval to capmatinib, marketed as Tabrecta by Novartis, for adult patients with metastatic non-small cell lung cancer, or NSCLC, whose tumors have a mutation leading to mesenchymal-epithelial transition, or MET, exon 14 skipping, as detected by an FDA-approved test. Previously, on May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib for the same indication.

13:00 EDT Ayr Wellness receives regulatory approval for adult-use sales in Somerville, MA - Ayr Wellness announced that the Massachusetts Cannabis Control Commission has granted a final license for adult-use cannabis at its Sira Naturals dispensary in Somerville. The Company also received approval to open the first phase of its cultivation expansion in Milford, Massachusetts. The CCC voted to approve both measures during its meeting on August 11, 2022.

12:39 EDT Marine Petroleum Trust trading halted, volatility trading pause

12:00 EDT Starry falls -15.1% - Starry is down -15.1%, or -58c to $3.25.

12:00 EDT Invitae falls -42.9% - Invitae is down -42.9%, or -$3.70 to $4.93.

12:00 EDT Butterfly Network rises 19.5% - Butterfly Network is up 19.5%, or $1.30 to $8.00.

11:42 EDT Disney CEO thinks movie business will be 'stable,' 'resilient' - Disney CEO Bob Chapek continues being interviewed on CNBC.

11:40 EDT Disney CEO says he sees no softening in theme park demand - Disney CEO Bob Chapek made the comments while being interviewed on CNBC.

10:57 EDT PNC Bank eliminates non-sufficient fund fees for consumer banking customers - PNC Bank announced that it will no longer charge any consumer deposit account customers non-sufficient fund fees. This marks the company's latest effort to enhance the financial well-being of its customers and extends the benefit it created with Virtual Wallet deposit accounts as part of the launch of Low Cash Mode in April 2021, PNC said. As a Main Street bank, PNC is focused on building a platform that empowers the financial well-being of its customers," said Alex Overstrom, head of Retail Banking for PNC. "Over the last several years, we've made significant enhancements to our overdraft solutions, all of which are designed to help our customers and give them better control of their financial future. Eliminating NSF fees on consumer deposit accounts is just another way we are helping our customers strengthen their financial wellness."

10:31 EDT Greenwich LifeSciences commences Phase III clincial trial of GLSI-100 - Greenwich LifeSciences announced the following: Phase III clinical trial, Flamingo-01, has officially started; Multiple sites have begun the screening and enrolling process; Flamingo-01 is evaluating the safety and efficacy of GLSI-100 in HER2/neu positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery. The commencement of the Phase III trial transitions the Company into pre-commercialization activities, which include: Working with the FDA in preparation for a BLA submission and commercial launch; Implementing a global strategy for launching GP2 in international markets outside the US and Europe; Initiating large scale manufacturing, packaging, and marketing. The Company anticipates the following additional activities/milestones: Phase III clinical trial progress and open label data will be presented at major conferences; Licensing discussions may accelerate as the interim analysis approaches; Other assets may be developed by acquisition or internal research, including T cell therapies that may be discovered in the Phase III trial by studying GP2's robust immunogenicity; Additional patents for GP2 based on the Phase III trial findings, manufacturing, and pharmacy procedures are planned to be filed to extend patent life.

10:21 EDT Pacific Biosciences trading resumes

10:17 EDT Pacific Biosciences trading halted, volatility trading pause

10:10 EDT Paige enters partnership with Sonora Quest Laboratories - Paige announced it will partner with Sonora Quest Laboratories to implement a fully digital pathology workflow at its laboratories. The goal of the digital transformation project is to improve existing diagnostic workflows and accelerate precision diagnoses for patients across Arizona. Under the partnership, Paige will provide Sonora Quest with the complete suite of Paige's AI-enabled digital pathology solutions, including the FullFocus viewer, Paige Prostate Detect and Paige Breast. Paige Prostate Detect is the first AI-based pathology product to receive de novo marketing authorization from the FDA, allowing in vitro diagnostic use via Paige's FDA-cleared FullFocus digital pathology viewer.

10:07 EDT ProKidney appoints John Maraganore, Jennifer Fox to board of directors - ProKidney Corp. (PROK) announced the appointments of John M. Maraganore, Ph.D. and Jennifer Fox to its Board of Directors. Maraganore is the owner of JMM Consulting, LLC and is a venture partner at ARCH Venture Partners, a venture advisor at Atlas Venture, an executive advisor at RTW Investments and a senior advisor at Blackstone Life Sciences, each of which are investment funds. Fox currently serves as Chief Financial Officer of Nuvation Bio (NUVB).

10:01 EDT Cedar Fair announces capital plans for 2023 operating plans - Cedar Fair Entertainment Company unveiled plans for the 2023 operating season across multiple properties in the U.S. and Canada. These include new themed areas at Carowinds in North Carolina and Cedar Point in Ohio, several major upgrades at Knott's Berry Farm in southern California, and 50th anniversary celebrations at Worlds of Fun in Missouri and Carowinds. In addition, several parks will be introducing a new generation of guests to some iconic rides and attractions from the past - such as the Wild Mouse at Cedar Point and Zambezi Zinger at Worlds of Fun -- that have been reimagined and recast for today's thrill seekers. There will be plenty of delicious new food and beverage options across the board, and park event calendars will be chock full of seasonal festivals and special celebrations that offer something fun for everyone in the family throughout 2023. Zimmerman said Cedar Fair's capital investments for 2023 will be the largest ever at approximately $200 million. In addition to new rides and attractions, Cedar Fair will continue to upgrade and expand food and beverage facilities across its portfolio in 2023, with a focus on providing signature menu and beverage items that tap into consumers' cravings for unique flavors and experiences they can't find anywhere else. These capital investments also will be aimed at improving the capabilities, technologies and efficiencies of the parks' food preparation and delivery systems.

10:00 EDT Super Group falls -15.7% - Super Group is down -15.7%, or -89c to $4.77.

10:00 EDT Invitae falls -39.0% - Invitae is down -39.0%, or -$3.36 to $5.27.

10:00 EDT Warby Parker rises 19.9% - Warby Parker is up 19.9%, or $2.82 to $17.00.

09:56 EDT Beyond Meat Chief Brand Officer sold 25,573 shares - In a regulatory filing, it was disclosed that Beyond Meat's Chief Brand Officer Beth Moskowitz sold 25,573 shares of the company's stock in transactions over August 8 to 10 with an average price of $39.95 and total transaction value of just over $1M.

09:49 EDT Alpha Teknova Inc trading resumes

09:47 EDT Six Flags falls -18.1% - Six Flags is down -18.1%, or -$4.66 to $21.15.

09:47 EDT Haemonetics shares rose 9% on Wednesday following Q1 results - Shares of Haemonetics close up about 9% yesterday after the company reported its Q1 earnings during the morning hours. The company's adjusted Q1 EPS was up 16% at 58c per share and its Q1 revenue rose 14% y/y to $261.5M, topping consensus estimates of 52c and $250.3M respectively. The company had also announced a new $300M share buyback authorization while its CEO Chris Simon stated: "Positive first-quarter results across businesses affirm our long-range plan for transformational growth. Robust growth in Plasma is evidence of improving momentum in plasma collections and Hospital is an increasingly powerful driver of growth, with Vascular Closure exceeding our expectations. Resilient manufacturing and supply enabled us to consistently deliver for customers and our capital allocation strategy will help create value for stakeholders as we leverage our capacity to accelerate growth in revenue and adjusted earnings per diluted share." In addition, Haemonetics narrowed higher its FY23 EPS view to $2.60-$2.90 from $2.50-$2.90 vs. consensus of $2.73 and also boosted its FY23 revenue growth outlook to 10%-14% form 6%-10%. This range implies $1.09B-$1.13B, vs. consensus of $1.08B.

09:47 EDT Dutch Bros rises 17.9% - Dutch Bros is up 17.9%, or $7.87 to $51.88.

09:46 EDT Main Street trading resumes

09:44 EDT Alpha Teknova Inc trading halted, volatility trading pause

09:39 EDT Veru trading halted, volatility trading pause

09:37 EDT Zhong Yang Financial Group Ltd trading halted, volatility trading pause

09:35 EDT NeoGames SA trading resumes

09:30 EDT NeoGames SA trading halted, volatility trading pause

09:28 EDT Helbiz to offer on-demand taxi services - Helbiz announced the beginning of a new chapter for its intermodal mobility offering, Helbiz Taxi. The micro-mobility company aims to integrate mobility services around the world in its app to widen the intra and extra urban mobility offerings to include vehicles from additional companies with the same vision. Starting out will be the integration of a selection of leading taxi operators in currently active markets. Helbiz users will be able to call a taxi on demand, pay, and rate the service all through one app.

09:26 EDT Texas Capital Bank appoints Vivek Misra as CCO - Texas Capital Bancshares announced that Vivek Misra has been appointed to serve as Executive Vice President, Chief Compliance Officer, effective immediately. He joins the Bank having served in senior compliance, operational, and enterprise risk positions for Wells Fargo, JPMorgan Chase, and Citigroup As Chief Compliance Officer, Mr. Misra will be responsible for leading the Bank's compliance risk management organization and will report directly to Mr. Storms.

09:25 EDT Pressure BioSciences receives approval to manufacture CBD products in Mass. - Pressure BioSciences announced approval for its South Easton MA facility to manufacture custom, compliant, hemp-derived CBD nanoemulsions under the processing/manufacturing license of its commercial partner, Canopy CBD Farms, Fitchburg, MA. Canopy CBD Farms is a Massachusetts licensed hemp processing and manufacturing company. Foreseeing the future of government regulations, CCF has strategically aligned itself with established FDA registered laboratories and manufacturers to bring the highest of standards and quality of hemp-derived CBD products. Canopy CBD Farms serves pharmaceutical and medical research companies, wishing to establish white label/co-branded manufacturing partnerships with cGMP, GLP manufacturers. CCF's partnerships will increase wholesale and retail distribution channels, with a ready-to-label line of high quality, salable hemp-derived CBD products, for a variety of uses and industries. Using the Company's patented Ultra Shear Technology platform, PBI will manufacture and sell - through a tolling processing center located in their South Easton MA facility - a new generation of effectively water-soluble hemp-derived CBD nanoemulsions, in bulk format. Expected to be purchased primarily by formulators and manufacturers, both in MA and throughout the U.S., PBI's nano-CBD is expected to introduce revolutionary precise and efficient dosing of hemp-derived, nanoemulsified CBD in a wide variety of shelf-stable, clean-label products, encompassing the nutraceuticals, personal care products, cosmetics, and food/beverage markets, to name a few.

09:23 EDT Jupiter Wellness enters multi-year licensing deal with SRM Entertainment - Jupiter Wellness announced that its SRM Entertainment division has entered into a multi-year licensing agreement with LAFIG Belgium for use of the Smurfs brand name and charcters to be featured on SRM's proprietary Sip With Me line of childrens hydration and table-top products. The Smurfs license was created by The Brand Liaison as licensing agent for SRM. Through the new license agreement, SRM will develop a full line of Sip With Me products including its patented double drinking straw tumblers. The Sip With Me Smurf product is expected to launch at retailers in July 2023 just prior to the all-new Smurfs film expected to hit theaters in 2024.

09:21 EDT Heico acquires Sensor Systems in cash, stock transaction - HEICO Corporation announced that its Electronic Technologies Group acquired all of the stock of Sensor Systems for a combination of cash and approximately 575,000 HEICO Class A Common Shares. Further financial details were not disclosed. HEICO stated that it expects the acquisition to be accretive to its earnings in the year following the acquisition. Chatsworth, CA-based Sensor is one of the world's leading designers and manufacturers of airborne antennas for commercial and military applications. Recognized as an international standard for many of its antennas, Sensor's products include, among others, Aircraft Direction Finding ("ADF"), Altimeter, Glideslope, Global Positioning System, L-Band, Marker Beacon, satellite communications, Total Collision Avoidance System, Very High Frequency ("VHF") and Very High Frequency Omni-directional Range antennas. Sensor's antennas are found on nearly all large commercial transport aircraft built in the last 50 years, along with numerous business and military aircraft. HEICO stated that Sensor will continue operating as its own business producing its full product range from its existing approximately 50,000 square foot, multi-building facility in Chatsworth, CA. HEICO stated that it does not expect any material turnover among Sensor's approximately 200 person staff to result from the acquisition. HEICO previously provided pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and received clearance to complete the acquisition.

09:19 EDT Greenlane secures $15M asset-based loan - Greenlane Holdings announced that it has closed on a $15 million asset-based loan. The loan is for a term of three years and will support Greenlane's strategic initiatives and working capital needs.

09:12 EDT Trex Company launches Grassroots Movement to expand plastic film recycling - Trex Company is enlisting communities and organizations to partner in its robust recycling efforts. The recently launched NexTrex Grassroots Movement provides a turnkey framework for municipalities, universities, nonprofits and other qualifying businesses to serve as centralized drop-off locations for recycling polyethylene plastic film while earning funds for their organizations. The Grassroots Movement is an expansion of the NexTrex recycling program, a nationwide material sourcing initiative for Trex, which manufactures its composite decking from 95% reclaimed material including a mix of industrial wood scrap and recycled polyethylene plastic film. The new grassroots program extends the benefits of Trex recycling to business and organizations that may not meet the volume criteria for the company's commercial recycling program. "The goals of our grassroots program are to engage more partners, establish more recycling outlets for consumer collection, and to increase overall accessibility to recycling by removing hurdles that prevent the organic growth of local plastic film recycling initiatives," explained Stephanie Hicks, materials sourcing manager for Trex Company. "The volume requirements established for our large commercial recycling partners are more than some organizations can attain or handle. The Grassroots Movement opens the program up to smaller but similarly eco-minded groups. It also expands the program beyond traditional grocery stores and retail drop-off locations, which can be limited in their collection abilities due to store hours or collection bin capacity constraints. By forming alternative partnerships, we hope to engage new and broader audiences in recycling."

09:10 EDT Q2 Holdings, Rocket team on digital home loan process to banks and credit unions - Q2 Holdings (QTWO) and Rocket Mortgage, America's largest mortgage lender and a part of Rocket Companies (RKT) announced a new partnership enabling Q2 banks and credit unions to offer Rocket Mortgage's digital home loan application experience, with live mortgage assistance, inside of Q2's online banking platform. "We're excited to add a premier brand like Rocket Mortgage to our Q2 Innovation Studio ecosystem," said Matt Flake, CEO of Q2. "This partnership, giving customers easy access to Rocket Mortgage's best-in-class digital offerings, adds another marquee solution to the Q2 Innovation Studio and provides an important and timely new option for our bank and credit union customers." The Q2 Partner Marketplace Program provides an app store-like experience so financial institutions can evaluate, select and deploy applications from a catalog of pre-integrated third-party products with no up-front investment. It enables banks and credit unions to provide their customers and members with innovative fintech applications, like access to Rocket Mortgage, integrated directly into their digital banking platform. Rocket Mortgage, which has closed more than $1.5 trillion in home loans over the last 37 years, will enable banks and credit unions to meet their account holder needs with an industry-recognized customer experience.

09:10 EDT Smart for Life announces 171% increase in Amazon sales, largest prime day - Smart for Life announced that it has achieved a 171% increase in Amazon sales on a year-over-year basis and its largest sales for Amazon Prime Day across all Smart for Life products, more than double its previous best day of Amazon revenue historically. "We are excited to announce these record results with Amazon, and we are extremely proud of our entire team for making this a reality," stated Darren Minton, Chief Executive Officer of Smart for Life. "This established growth of our business through online sales, including Amazon Prime, demonstrates our ability to capitalize on meaningful drivers for organic growth. This supports Smart for Life's vision and commitment to bringing our health and wellness products to new customers in the United States and around the world as we continue expanding awareness of our brand." Smart for Life achieved these record Amazon sales for Amazon's Prime Day initiatives this past month on July 12 -13, 2022. During the event, Smart for Life sold thousands of protein bars, gummies, cookies and other Health & Wellness products through Amazon, resulting in the highest ever Amazon Prime Day sales for the Company on record.

09:09 EDT Stronghold Digital Mining reschedules Q2 conference call - Stronghold Digital Mining is rescheduling its second quarter 2022 earnings conference to Monday, August 15 at 5:00 p.m. Eastern Time. A press release detailing these results will be issued after the close of trading on the same day. Stronghold management will provide prepared remarks, followed by a question-and-answer period. Date: Monday, August 15, 2022 Time: 5:00 p.m. Eastern time

09:05 EDT Abbott's TBI Plasma test shows efficacy in concussion recovery study - Abott announced that a new study published in The Lancet Neurology demonstrates the ability of two blood-based biomarkers to predict how someone will recover from traumatic brain injury, or TBI. Testing for these two biomarkers in the immediate aftermath of an injury can help health care providers determine the best way to treat and care for patients, how severe the injury is, the expected course of recovery and the longer-term implications of the TBI. The markers were measured using Abbott's i-STAT TBI Plasma test, as well as on the company's Arhcitect core laboratory instrument using research prototype assays, both of which helped predict recovery. Researchers found that high values of the biomarkers, GFAP and UCH-L1, correlate with death and severe injury. Abbott's i-STAT TBI Plasma test is the first rapid test on a portable analyzer to receive FDA 510(k) clearance and can help determine the need for a computed tomography scan. Test results are available approximately 15 minutes after a plasma sample is inserted in the test i-STAT cartridge. Abbott is pursuing FDA clearance under Breakthrough Designation for the TBI test on its Alinity i and ARCHITECT core laboratory instruments. Abbott's TBI test on Alinity i is CE Marked and available outside the U.S. Abbott's TBI blood test was developed in collaboration with the U.S. Department of Defense,

09:03 EDT Reed's launches Zero Sugar Stormy Mule - Reed's announced the launch of the Reed's Zero Sugar Stormy Mule across the West Coast. Building off the Classic Mule, the Stormy Mule is the ultimate ready-to-drink, RTD crafted beverage from the #1 Ginger Beer makers of in the US. The Stormy Mule is a keto-friendly take on the iconic Dark and Stormy and is naturally brewed with REAL, fresh ginger root and natural rum flavor with no added sugars. Hitting the shelves just in time to provide a tasty and refreshing libation to kick-back with during the August sun, the new Zero Sugar Stormy Mule contains 7% alcohol, and a light-spice profile with no artificial colors, gluten, GMOs or caffeine.

09:03 EDT Origin Agritech signs new contract planting agreement with Sichuan Yingdafeng - Origin Agritech announced that the company has signed a contract planting agreement with farming company Sichuan Yingdafeng Agriculture Tech Co., Ltd. Under the terms of the agreement, Sichuan Yingdafeng will grow 100,000 mu of Origin's NEC corn for the 2023 growing season. Origin will provide the seed and planting support services and guarantees to purchase all the corn once harvested. The corn will be sold to end users based on long-term supply agreements signed with feedstock companies and hog farmers. The corn will be grown in the Sichuan Province allowing Origin to expand geographically and supply the corn to hog farms in that region, thus improving logistics and limiting expensive shipping costs.

09:01 EDT Fresh Vine releases Brut Rose Sparkling Wine - Fresh Vine Wine announced the release of its Brut Rose Sparkling Wine, the seventh varietal in its expanding line up of premium wines.

08:55 EDT Critical Elements completes engineering study for Lithium Hydroxide plant - Critical Elements Lithium is pleased to announce completion of an Engineering Study for a Lithium Hydroxide Monohydrate plant. Consistent with the Corporation's conservative, phased approach, the study is based on a standalone conversion plant and does not constitute a "mineral project" for the purposes of National Instrument 43-101 - Standards of Disclosure for Mineral Projects. Furthermore, the plant does not form part of the Corporation's Rose Lithium-Tantalum project which consists solely of a mine to produce spodumene and tantalum concentrates. As at the date hereof, notwithstanding today's announcement, the Corporation is not in a position to confirm that a Lithium Hydroxide Monohydrate plant will ever be implemented. This strategic milestone could enable Critical Elements to become an important player in the North American Lithium market. Generating separate, standalone engineering studies for the Rose Lithium-Tantalum project and the Lithium Hydroxide Monohydrate plant may optimize the outcome of discussions with potential strategic investors and end-users. The Engineering Study for a Lithium Hydroxide Monohydrate plant is based on a yearly production of 30,670 tonnes of high-quality battery grade lithium hydroxide monohydrate from 220,587 tonnes of spodumene concentrate purchased solely on the world market on long term contract basis. The study does not rely on or is not based on any purchases of spodumene concentrate from the Corporation's Rose Lithium-Tantalum project. The operating parameters for the Engineering Study were taken from the joint Metso Outotec and Critical Elements Lithium Corporation piloting programs.

08:52 EDT Jupiter Wellness division enters licensing agreement with LAFIG Belgium - Jupiter Wellness announced that its SRM Entertainment division has entered into a multi-year licensing agreement with LAFIG Belgium for use of the Smurfs brand name and characters to be featured on SRM's proprietary Sip With Me line of children's hydration and table-top products. The Smurfs license was created by The Brand Liaison as licensing agent for SRM. Through the new license agreement, SRM will develop a full line of Sip With Me products including its patented double drinking straw tumblers. The Sip With Me Smurf product is expected to launch at retailers in July 2023 just prior to the all-new Smurfs film expected to hit theaters in 2024.

08:48 EDT Diversified Energy announces alignment of Revolving Credit Facility - Diversified Energy Company announces enhanced alignment of its Revolving Credit Facility led by KeyBank National Association with its stated ESG initiatives through an amendment converting the Facility into a Sustainability-Linked Loan. Diversified's integration of the SLL principles emphasizes the Company's commitment to continuous ESG improvement by incorporating the following three sustainability-linked performance targets: Greenhouse gas emissions intensity reduction targets; Asset Retirement targets above current levels; Safety-related performance targeting a decrease in Total Recordable Incident Rate; The amendment also extends the SLL's maturity to August 2026, reaffirms the borrowing base of $300 million and included no other material changes to pricing or terms.

08:44 EDT DMG Blockchain Solutions mined 54 bitcoin in July - In July 2022, DMG mined 54 bitcoin and added no additional mining capacity. DMG expects to receive additional miners during August 2022 and thus anticipates an increase in its mining capacity once the bitcoin miners are installed and operating. DMG's bitcoin balance as of July 31, 2022 was 324 BTC. DMG is on-target with respect to its original schedule for received miner deliveries for growing its hashrate to 1 EH/s by the end of 2022, subject to the receipt, installation and operation of the additional miners.

08:41 EDT Shoals Technologies group awarded 53.4 MWdc Honduras Solar Project - Shoals Technologies Group announced it has entered into an agreement with Consultoria e Inversiones Hondurenas en Energia S.A. to supply its BLA system solution for the 53.4 MWdc San Jose solar project, located in Olanchito, Honduras. "We're proud to partner with CIHESA to supply our BLA system for the San Jose solar project in Honduras," said Ben Macias, Senior Vice President of Sales and Marketing at Shoals. "As we expand our footprint internationally, our partners abroad are realizing the benefits of our BLA system that significantly reduces field work while improving quality, reliability, and safety." The project is expected to begin power generation by the end of fourth quarter 2023.

08:39 EDT Calavo Growers announces Jalisco facility open for exports to US - Calavo Growers announced official certification and opening of Jalisco packing facility for the American market. The demand for avocados is growing year-over-year not only in the US but also internationally. Calavo has been supplying customers with this heart healthy fruit for nearly 100 years. "Today, we are proud to announce that we have expanded our partnership with our Mexican growers from Michoacan to Jalisco," said Dionisio Ortiz, Vice President Calavo de Mexico. "This will elevate our sourcing capabilities to an even higher level to provide US tables with the best quality avocados on the market while also providing opportunities to supply the international community."

08:39 EDT NYS DMV awards Iteris five year contract for CVIEWplus SaaS solution, no terms - Iteris announced that it has been awarded a new contract by the New York State Department of Motor Vehicles for Iteris' CVIEWplus software-as-a-service solution. Under the terms of the five-year contract, Iteris will provide the cloud-hosted CVIEWplus solution, including oversize/overweight permit system integration to the NYS DMV. Iteris' SaaS solution supports the state's goals of maintaining compliance with the Federal Motor Carrier Safety Administration's Innovative Technology Deployment program, improving goods movement, and enhancing safety for truck drivers and roadside inspectors. Iteris will upload International Fuel Tax Association data to the FMCA's Safety and Fitness Electronic Records system and International Registration Plan data to the IRP Data Repository and download interstate and federal data from FMCSA systems that are critical for NYS DMV's ITD program compliance.

08:38 EDT WeWork appoints SBGI CEO Alex Clavel to board - WeWork announced that Alex Clavel, CEO of SoftBank Group International, or SBGI, has joined WeWork's board of directors, effective August 9. Clavel succeeds Michel Combes, the former CEO of SBGI, who had served on WeWork's board since October 2020. Clavel has experience with both private and public companies, having been responsible for managing SoftBank's international platform of investments, including WeWork. He currently serves as a director on numerous internal SoftBank and external portfolio company boards.

08:34 EDT Landos Biopharma expects cash to fund operations for at least next 12 months - As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of $55.8 million, which it believes will be sufficient to fund its planned operations for at least the next 12 months. Upon completion of its portfolio prioritization review later this year, the Company will provide further details into its operating plans and capital resources.

08:30 EDT Apollo Global closes $2.35B in commitments to Apollo Origination Fund I - Apollo announced that it has closed on approximately $2.35B in commitments for Apollo Origination Partnership Fund I, its inaugural fund dedicated to large corporate direct lending. The new fund contributes to Apollo's more than $50B of AUM across its direct lending strategies and platforms. "Apollo Origination Partnership is designed to leverage our origination capabilities and credit expertise to provide scaled capital solutions. The Fund builds on our decades of experience lending to large corporates and sponsor-backed companies to help achieve their goals, while generating attractive risk-adjusted returns for our investors," said Apollo Partner James Vanek. "We are grateful for the strong investor support and believe scaled direct origination is a long-term opportunity which is still in its infancy." Apollo intends to continue to build out its large corporate direct origination capabilities in partnership with its global institutional and wealth management investor base.

08:28 EDT aTyr Pharma receives Fast Track Designation for efzofitimod - aTyr Pharma announced that the U.S. Food and Drug Administration has granted the company Fast Track designation for its lead therapeutic candidate, efzofitimod, for the treatment of pulmonary sarcoidosis, a major form of interstitial lung disease. "The Fast Track designation for efzofitimod underscores the significant need for a new therapy that provides clinically meaningful outcomes for patients living with pulmonary sarcoidosis," said Sanjay Shukla, M.D., M.S., President and CEO of aTyr. "Fast Track designation reinforces the potential of this novel immunomodulator to be a transformative, disease modifying therapy and address a major unmet need for the sarcoidosis community. We are currently investigating efzofitimod in a global pivotal Phase 3 study called EFZO-FIT(TM) and we look forward to the opportunity to work closely with the FDA to potentially expedite the delivery of a new treatment to patients in need."

08:26 EDT Climb Channel Solutions announces partnership with Cato Networks - Climb Channel Solutions announced a partnership with Cato Networks converging Cato SD-WAN and a cloud-native security service edge, Cato SSE 360, into a global cloud-native service.

08:25 EDT Graphite Bio announces first patient dosed GPH101 for sickle cell treatment - Graphite Bio announced that the first patient has been dosed with GPH101, now called nulabeglogene autogedtemcel , in the company's Phase 1/2 CEDAR trial in people with sickle cell disease. Nula-cel is an investigational gene editing therapy designed to directly correct the genetic mutation that causes SCD and definitively cure the disease. "For decades, the goal of gene editing has been to precisely correct genetic mutations that cause disease. Today, we took an important step toward achieving that goal by dosing our first patient with nula-cel, the first investigational therapy designed to correct a mutated gene to normal. This first use of high-efficiency precision DNA repair to correct a genetic mutation is an important milestone not only for our company but also for the gene editing field and, hopefully, for the sickle cell community," said Josh Lehrer, M.D., M.Phil., chief executive officer of Graphite Bio. We continue to make tremendous progress with the development of nula-cel, which in preclinical studies successfully corrected the sickle cell disease mutation, directly reducing sickle hemoglobin and restoring healthy adult hemoglobin to potentially curative levels," Lehrer continued. "We believe nula-cel could be a definitive cure for sickle cell disease, with the potential to address all complications associated with this life-threatening disease. We look forward to reporting initial proof-of-concept data from the CEDAR trial in mid-2023."

08:24 EDT Fortress subsidiary announces grant that could provide over $20M in funding - Fortress Biotech announced that Triplex received a grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health that could provide over $20M in non-dilutive funding. This competitive award will fund a multi-center, placebo-controlled, randomized Phase 2 study of Triplex for control of CMV in patients undergoing liver transplantation. The study will be conducted across up to 15 nationally recognized transplant centers in the United States. Lindsay Rosenwald, M.D., Fortress' Chairman and Chief Executive Officer, said, "We are very excited that Triplex, being progressed by our subsidiary Helocyte, is the subject of this substantial grant from the NIAID/NIH, as it will allow us to investigate its potential to control CMV in patients undergoing liver transplant. CMV is a common opportunistic infection in transplantation, directly impacting post-transplant outcomes and patient mortality.i The COLT trial will build upon the growing patient database of Triplex, which has already been dosed safely in over 100 subjects and is the subject of multiple other ongoing and planned studies."

08:19 EDT Pasithea Therapeutics announces results of preclinical study of PAS002 - Pasithea Therapeutics announced positive results from a preclinical proof of concept study of PAS002, its tolerizing vaccine program in multiple sclerosis. In this proof of concept study, relapsing paralysis was established in a mouse model of relapsing-remitting experimental autoimmune encephalomyelitis, the standard animal model of MS. In three groups, a proprietary DNA cassette was engineered to encode GlialCAM and injected to potentially block acute disease and its relapse. These DNA molecules were designed to protect against paralytic disease by tolerizing the immune system so it would not attack myelin in the brain and spinal cord. The engineered DNA molecule creates tolerance, working like an 'inverse vaccine', and was administered intra-muscularly at days 0, 3, 7, 10, and 14. The study had a standard duration of 32 days. Key findings from the study include: treatment with a DNA tolerizing 'inverse vaccine' delayed the onset of paralysis when compared to vehicle; a statistically significant reduction in disease severity, when compared to vehicle; a statistically significant reduction in relapse severity, when compared to vehicle; treatment with a DNA vaccine prevented disease in approximately 50% of the mice, when compared to vehicle. Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea, stated, "We're thrilled with the strong preclinical efficacy data shown in this study. Although early stage, we believe these results demonstrate the promise and validity of our tolerizing approach, which is built on recent data on the biological mechanism linking infection with EBV with the development of MS. We have filed a provisional patent application and we will continue to rapidly pursue the PAS002 drug development program."

08:15 EDT ChromaDex reports CFO Kevin Farr terminated without cause - In a regulatory filing last night, ChromaDex disclosed that on August 10, Kevin Farr was terminated without cause as Chief Financial Officer of the company, and as an officer, employee, and director of the company and any subsidiaries of the company in which he serves in any of those capacities, effective as of August 12. Also on August 10, the board of directors of ChromaDex appointed Brianna Gerber as SVP, Finance / Interim Chief Financial Officer, effective as of August 11, to replace the vacancy created by Farr's termination. Gerber previously served as Vice President of Finance and Investor Relations of ChromaDex since September 17, 2018, and prior to that served in multiple leadership roles at Mattel (MAT) since 2013, the filing noted.

08:14 EDT PHX Energy Services receives TSX approval for renewal of NCIB - PHX Energy Services announced that the Toronto Stock Exchange has accepted PHX Energy's notice of intention to renew its normal course issuer bid for a further one-year term. The previous NCIB expires on August 15, 2022. Pursuant to the Corporation's previous NCIB, the Corporation purchased in the open market through the facilities of the TSX and through other alternative Canadian trading platforms and cancelled an aggregate of 1,499,900 common shares of the Corporation at an average price paid of $4.50 per Common Share. Under the renewed NCIB, PHX Energy may purchase for cancellation, from time to time, as PHX Energy considers advisable, up to a maximum of 3,622,967 Common Shares, which represents 10% of the Corporation's public float of 36,229,675 Common Shares as at August 3, 2022. Purchases of Common Shares may be made on the open market through the facilities of the TSX and through other alternative Canadian trading platforms at the prevailing market price at the time of such transaction. The actual number of Common Shares that may be purchased for cancellation and the timing of any such purchases will be determined by PHX Energy, subject to a maximum daily purchase limitation of 27,486 Common Shares which equates to 25% of PHX Energy's average daily trading volume of 109,947 Common Shares for the six months ended July 31, 2022. PHX Energy may make one block purchase per calendar week which exceeds the daily repurchase restrictions. Any Common Shares that are purchased by PHX Energy under the NCIB will be cancelled. The NCIB will commence on August 16, 2022 and will terminate on August 15, 2023 or such earlier time as the NCIB is completed or terminated at the option of PHX Energy. PHX Energy believes that within a continued volatile market environment, at times, the prevailing market price does not reflect the underlying value of its Common Shares and the repurchase of its Common Shares for cancellation represents an attractive opportunity to enhance PHX Energy's per share metrics and thereby increase the underlying value to its shareholders. PHX Energy intends to use the NCIB as another tool to enhance total long-term shareholder returns in conjunction with management's disciplined capital allocation strategy.

08:12 EDT MindMed co-founder Scott Freeman issues letter to Board - MindMed's co-founder and former Chief Medical Officer Scott Freeman and director of FCM MM Holdings has sent a letter to the Board of Directors of MindMed calling on the Board to adopt a new strategic plan proposed by FCM including: refocusing on its core drugs, cutting cash burn, and terminating MindMed's at-the-money equity offering. Freeman has offered to provide MindMed his expertise as a director on MindMed's board. FCM believes MindMed has underperformed-operationally, financially, and strategically-as a direct result of management's "lack of focus on its core drugs". FCM contends that MindMed can bring MM-120 to market in four years rather than seven to eight years, by re-classifying MindMed's Phase IIb study on MM-120 to a Phase III study. FCM also proposes that the xompany reduce costs from forty-five million dollars per year to under twenty-five million dollars and that the unnecessary and dilutive at-the-money offering should be eliminated.

08:12 EDT Blue Apron introduces new Tailgating Box 'in time for football season' - Blue Apron introduces a new Tailgating Box as part of its limited-time, seasonal meal kits, available with or without a subscription. "Right in time for football season, the Tailgating Box features classic game day recipes with an elevated twist, designed to help customers celebrate their favorite team this fall with minimal planning involved," said Blue Apron in a statement. "Our seasonal, occasion-based meal kits provide customers with 'best of season' proteins, produce and ingredients, giving them everything they need to celebrate special moments with ease," said John Adler, Blue Apron's Vice President of Culinary. "Following the success of the Summer Lobster Box, our Tailgating Box is a new and exciting way for customers to experience game day with an array of delicious recipes."

08:05 EDT FuboTV adds SportsGrid network - FuboTV has added SportsGrid, a 24-hour sports wagering streaming network. The network features real-time sports news, data, analytics, and statistics. SportsGrid's reporting and analytic platform includes daily odds, lines, matchups, injury reports, statistics, news, and more across the NFL, NBA, MLB, NHL, college sports, golf, tennis, and soccer.

08:03 EDT Aviat Networks issues open letter to Ceragon Networks shareholders - Aviat Networks (AVNW) issued an open letter to shareholders of Ceragon Networks Ltd. (CRNT) to "correct the latest false claims and mischaracterizations" made by Ceragon's Board of Directors in its August 8, 2022 letter to shareholders. The letter says in part: "Aviat has given the Board many opportunities to consider and negotiate a transaction that would provide shareholders like you immediate value at a significant premium. Rather than engage in fruitful discussion, the Board has delayed, deferred and attempted to distract you with a series of false and misleading arguments designed to disguise their persistent failure to deliver value. Earlier this week, the Board rejected Aviat's revised proposal to acquire Ceragon for $3.08 per share in cash and stock, in another letter that distorts the record and which is replete with false claims and mischaracterizations. We're writing to you today to once again set the record straight... The truth is that Ceragon is struggling on its own, and is not going to achieve outlandish price targets, or even its own projections. We continue to believe that Ceragon would see tremendous advantages from being part of a larger platform with more scale and resources as part of Aviat. In fact, ISS noted that a "lack of clear progress" could send Ceragon's stock lower in the absence of a transaction, including one with Aviat. Despite Ceragon's claims to the contrary, the Board has repeatedly erected roadblocks to exploring a value creating transaction with Aviat at any price, even declining to name their own price when offered the opportunity. What we now recognize is that this Board cannot come to its senses, because the Board lacks the necessary independence to do the right thing for shareholders."

07:56 EDT AC Immune to host KOL webinar on vaccinations - AC Immune announced that it will host a key opinion leader webinar on vaccinations to treat and prevent Alzheimer's and Parkinson's diseases on Wednesday, August 24, 2022 at 10:00 AM ET / 4:00 PM CET. The webinar will feature a presentation from KOL Cynthia A. Lemere, Ph.D., of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital and Harvard Medical School in Boston. During her presentation, Dr. Lemere will discuss the current immunotherapy landscape and novel therapeutic approaches to treat and prevent neurodegenerative diseases, with a focus on biomarkers and target proteins for active vaccination approaches. Additionally, members of AC Immune's management team will provide an overview of the Company's precision medicine approach and its industry-leading pipeline of active vaccines stemming from its differentiated technology platform. Management will also discuss the advantages offered by the innovative biomarker-based clinical trial designs being utilized in its Alzheimer's and Parkinson's disease programs.

07:54 EDT Rogers Sugar expects improved financial performance in 2022 - As a result of the strong demand and improved margins, we are experiencing in our Sugar segment, we continue to expect improved financial performance in 2022 as compared to 2021. The strength in our Sugar segment is expected to offset higher costs from inflationary pressures and lower demand in the Maple segment.

07:52 EDT Monarch Mining presents results of 2022 resource estimate for Croinor project - Monarch Mining reports the results of its 2022 mineral resource estimate for its Croinor Gold project, located 55 kilometres east of Val-d'Or. The mineral resource estimate assumes solely potential underground mining. The estimate was prepared by Olivier Vadnais-Leblanc, P.Geo., Carl Pelletier, P.Geo. and Eric Lecomte, P.Eng., of InnovExplo Inc., all three qualified and independent persons as defined by National Instrument 43-101. The estimate was prepared using all available information, including the results from the latest drilling programs. The effective date of the mineral resource estimate is June 17, 2022. "This is excellent news for Monarch as it enables us to reach another milestone in terms of resources backed by NI 43-101 reports for each of our four gold projects," said Jean-Marc Lacoste, President and Chief Executive Officer of Monarch. "Now that we have confirmed Croinor's mineral resources more rigorously and with a higher degree of certainty, we will focus on finding the right partner to develop this promising project, which covers over 150 km2 of land and remains open laterally and at depth."

07:51 EDT Marimed's Nature's Heritage Brand sponsors Cultivators Cup - MariMed announced its Nature's Heritage brand of craft flower and concentrates is a Presenting Sponsor of Cultivators Cup, the leading cannabis industry festival and awards competition in Massachusetts. A celebration of cannabis culture and the best cannabis products produced in the state, Cultivators Cup will be held September 3rd and 4th at The Palladium Outdoors entertainment venue in Worcester, MA. The Cultivators Cup awards show will recognize the top cannabis cultivators, manufacturers, and brands in Massachusetts across several categories, including flower, concentrates, and more, as judged by consumers.

07:48 EDT Lucira Health announces Health Canada authorization for at home COVID, flu test - Lucira Health announced that Health Canada has granted Authorization under Interim Order for the emergency use and commercialization of the first and only at-home test for COVID & Flu. The Lucira COVID-19 & Flu Test is a 99% accurate rapid molecular test that delivers results in 30 minutes or less from one shallow nasal swab. "When influenza and Covid-19 co-circulate this winter, millions who don't feel well will be asking 'is it Covid-19 or flu?' so they can take the appropriate action to get better. Only the Lucira COVID-19 & Flu Test, a single at-home test with 99% accuracy, can answer this question immediately," said Erik Engelson, President and Chief Executive Officer of Lucira Health. "We appreciate Health Canada for its careful and thorough assessment of the Lucira COVID-19 & Flu Test. This timely action is expected to help Canadians accurately test at-home in advance of flu season, keep more people out of the emergency departments, and provide a rapid treatment pathway."

07:46 EDT ALX Oncology announces first patient dosed in Phase 2 trial of evorpacept - ALX Oncology (ALXO) announced the initiation of a Phase 2 investigator-sponsored study of evorpacept, a next generation CD47 blocker, in combination with ERBITUX and KEYTRUDA, Merck's (MRK) anti-PD-1 therapy, in patients with refractory microsatellite stable metastatic colorectal cancer who have progressed on at least two lines of systemic therapy. This is an open-label, multi-center, single-arm phase 2 clinical trial. Eli Lilly (LLY) and Company and Merck, known as MSD outside the United States and Canada, will respectively provide ERBITUX and KEYTRUDA to support this study.

07:44 EDT Ree Automotive debuts P7-B, an electric class 3 box truck - REE Automotive announced P7-B, a class 3 box truck built on a P7 cab chassis, following intensive customer evaluations at REE's UK Engineering Center. The new P7-B is part of a fleet of vehicles available to prospective customers to evaluate, test, and experience the unique agility, performance, and design enabled by REE's novel REEcorner x-by-wire technology. The class 3, all-by-wire electric truck, designed and built by REE based on its P7 modular chassis, targets the important and growing commercial EV mid- and last-mile delivery market, with applications such as 16-foot vans and delivery trucks. It was built in response to market needs and represents a potential opportunity for REE to present fleets with complete vehicles. This P7 box truck configuration offers increased interior space for passengers and cargo and a low step-in height while targeting a maximum speed of 75 mph, max range of 150 miles, up to 4,400 lbs payload, and vehicle weight ratings of up to 14,000 lbs.

07:41 EDT Nabriva Therapeutics completes patient enrollment in Phase 1 trial of XENLETA - infective agents to treat serious infections, announced the completion of patient enrollment in its Phase 1 clinical trial to assess the safety and pharmacokinetics of oral and intravenous XENLETA in adult patients with cystic fibrosis. "We are happy to announce enrollment has been completed in this important study to evaluate the potential of XENLETA in the management of bacterial infections in patients with cystic fibrosis," said Christine Guico-Pabia, M.D., MBA, MPH, Nabriva's Chief Medical Officer. "XENLETA has the potential to provide a well-tolerated oral and intravenous anti-MRSA treatment option with a novel mechanism for this difficult to treat patient population." Dr. Guico-Pabia added, "With enrollment now complete, we expect to report topline data in the first quarter of 2023. We look forward to sharing the results of this study with the medical community. Thank you to the investigators and patients who participated in this important trial, as well as the Cystic Fibrosis Foundation for their support."

07:38 EDT Wave Life Sciences expects cash to fund requirements to end of 2023 - Wave expects that its existing cash, cash equivalents and short-term investments will enable the company to fund its operating and capital expenditure requirements to the end of 2023.

07:33 EDT iKena Oncology expects cash to fund operations through mid-2024 - Ikena had $192.8 million in cash, cash equivalents, marketable securities as of June 30, 2022, as compared to $232.2 million as of December 31, 2021. Ikena believes its available cash, cash equivalents, and marketable securities will be sufficient to meet its operating requirements through mid-2024. Net cash used in operating activities was $19.5 million for the three months ended June 30, 2022, as compared to $15.7 million of cash used in operating activities for the same period in 2021.

07:33 EDT Monte Rosa Therapeutics sees cash funding operations into late 2024 - Cash Runway into Late 2024 with $299.5 Million in Cash, Cash Equivalents, Restricted Cash and Marketable Securities as of June 30, 2022

07:31 EDT ProQR Therapeutics to focus exclusive on Axiomer RNA-editing platform - ProQR Therapeutics provided an update on its ophthalmology programs following feedback from the European Medicines Agency, EMA, related to sepofarsen and will now focus exclusively on its Axiomer RNA-editing technology platform. Following the results from the sepofarsen Illuminate trial, the EMA has recommended an additional clinical trial be conducted for sepofarsen prior to submitting a Marketing Authorisation Application, MAA. In light of this feedback and in order to continue advancement of the portfolio of ophthalmic product candidates, including sepofarsen for LCA10 and ultevursen for USH2A-mediated Usher syndrome and retinitis pigmentosa, the Company will seek to identify a strategic partner to take the ophthalmology portfolio forward. Strategic Focus and Operational Update: Further to the announcement in April 2022 on the Company's strategy, going forward, ProQR will focus exclusively on accelerating the development of its Axiomer RNA-editing platform technology. Initial therapeutic areas include liver and CNS, which we believe have strong alignment with ProQR's oligonucleotide delivery approaches. ProQR's strategic growth initiatives related to the advancement of its Axiomer RNA editing platform include both in-house development of select pipeline programs using the technology and a partnering strategy for the platform. The Company continues to execute on its global licensing and research partnership with Eli Lilly, focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system, and may selectively enter additional partnerships designed to advance and capture the full potential value of the platform. ProQR has established a leading IP estate in the ADAR-editing space related to its RNA-editing technology and the platform's broad applicability has significant potential to treat a number of diseases. The Company will provide further updates on the Axiomer strategy, including announcing its internal development targets in late 2022/early 2023. Based on the wind down of sepofarsen and ultevursen clinical trials and associated workforce reduction, ProQR will realize cost savings in headcount, program, and related support activities, which are expected to extend ProQR's cash runway into 2026. The cash runway into 2026 excludes any revenue generated from the Company's existing partnership and any potential new partnering deals. "As we prioritize the development of our Axiomer RNA editing platform technology, we believe partnering our ophthalmology assets is the best strategy to drive these programs forward to patients," said Daniel de Boer, Chief Executive Officer of ProQR Therapeutics. "The feedback we received from the EMA is helpful in designing an additional registration trial for sepofarsen based on the learnings from the Illuminate trial and we will seek a strategic partner for the further development of our ophthalmology programs, including sepofarsen and ultevursen. As a company dedicated to developing therapies to improve the lives of patients, we will offer clinical trial participants continued access to currently available sepofarsen or ultevursen. I want to thank the employees who will be separating from ProQR for their significant contributions in advancing sepofarsen and ultevursen to this stage, as well as the patients, providers, and supporters of these programs."

07:29 EDT XPO Logistics appoints Reinhardt as CCO of RXO spin-off - XPO Logistics (XPO) announced that Nina Reinhardt will become the chief communications officer, CCO, of RXO, the planned spin-off of XPO's brokered transportation platform. Reinhardt will join XPO as chief communications officer of the North American transportation division, effective immediately, and will lead RXO's communications organization when the separation is complete. She reports to Drew Wilkerson, who, as previously announced, will be chief executive officer of RXO, and currently serves as president, transportation - North America. Reinhardt joins the company from Honeywell (HON), where her 18-year tenure included leadership roles in external and internal communications, public affairs and investor relations.

07:23 EDT EQRx expects cash to fund operations at least into 2025 - Cash, cash equivalents and short-term investments totaled $1.6 billion at June 30, 2022. EQRx expects to maintain sufficient capital resources to fund anticipated operations at least into 2025.

07:21 EDT Optinose expects XHANCE net revenues for FY22 to be between $85M-$92M - The Company expects XHANCE net revenues for the full year of 2022 to be between $85 - $92 million. Previously, the Company expected XHANCE net revenues for the full year of 2022 to be at least $90 million. In addition, the Company expects full year 2022 XHANCE average net revenue per prescription to be at least $220. Previously the Company expected full year 2022 XHANCE average net revenue per prescription to be at least $210.

07:20 EDT Synlogic announces new drug candidate in partnership with Ginkgo Bioworks - Synlogic (SYBX) announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks (DNA), the leading horizontal platform for cell programming. The new candidate, SYNB2081, is a Synthetic Biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following the investigational new drug candidate SYNB1353 for the potential treatment of homocystinuria.

07:19 EDT Hookipa Pharma announces upcoming milestones - Upcoming Anticipated Milestones: Phase 2 HB-200 data in combination with pembrolizumab in HPV16+ head and neck cancer: First-line initial data expected in the second half of 2022, Second-line initial data expected in the second half of 2022. Randomized Phase 2 HB-200 study in combination with pembrolizumab in first-line for HPV16+ HNSCC: First half of 2023. Hepatitis B therapeutic IND: 2022. Prostate cancer First Patient Enrolled expected in first quarter of 2023

07:16 EDT Ginkgo Bioworks, Rwanda Development Board sign MoU - Ginkgo Bioworks and the Rwanda Development Board, representing the government of the Republic of Rwanda, announced that they have entered into a Memorandum of Understanding with the intent of developing and implementing new biosecurity capabilities in Rwanda. The initial goal of the planned partnership is to support Rwanda's public health institutions as they work to address biosecurity challenges in the region. Ginkgo, through its biosecurity and public health initiative, Concentric by Ginkgo, plans to collaborate on the ground with RDB to equip these institutions with biosecurity tools and training as well as the secure data infrastructure they need to leverage automation, data analysis, bioinformatics capabilities, and other critical genomic sequencing technologies.

07:15 EDT Wabash expands EcoNex Technology production in Minnesota - Wabash announced it is expanding manufacturing capacity of EcoNex Technology to address customer demand and equipment challenges that refrigerated carriers have faced for years, including thermal efficiency, strength, weight and asset life. As part of this expansion, Wabash is investing an additional $20M at its 53-acre facility in Little Falls, Minn., and adding over 200 jobs by the end of 2023.

07:14 EDT Trevena expects cash to fund requirements into mid-2023 - Cash and cash equivalents were $49.5 million as of June 30, 2022, which the Company believes will be sufficient to fund the Company's operating expenses and capital expenditure requirements to mid-2023. The cash balance does not include net proceeds from the Company's July 2022 registered direct offering of preferred shares.

07:12 EDT Chart Industries and Agricultural Gas sign MOU for CO2 enrichment solutions - Chart Industries signed a Memorandum of Understanding with The Agricultural Gas Company to collaborate on marketing CO2 enrichment solutions to the agricultural market that incorporate leading technology from both companies. AG Gas CO2 enrichment systems and Chart cryogenic tanks are already being deployed together in the California market. The system responds in real-time to environmental factors including light, temperature and ventilation, and is fully-compliant with safety regulations associated with human exposure to CO2.

07:11 EDT TransUnion raises quarterly dividend to 10.5c per share - This marks the second increase to the dividend since the first quarter 2021. The dividend will be payable on September 9 to shareholders of record on August 25.

07:07 EDT Fulcrum Therapeutics expects cash to fund operations into mid-2024 - As of June 30, 2022, cash, cash equivalents, and marketable securities were $169.0 million, as compared to $218.2 million as of December 31, 2021. Based on current operating plans, including successful implementation of the operational realignment, Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into mid-2024.

07:04 EDT TreeHouse to divest portion of Meal Preparation business for $950M - TreeHouse announced that it has reached a definitive agreement to sell a significant portion of its Meal Preparation business to Investindustrial for $950M. The $950M transaction value represents approximately 13.6x times 2022 adjusted earnings before interest, taxes, depreciation and amortization, or EBITDA, for the divested business. The transaction consists of approximately $530M in cash at closing and approximately $420M in senior secured debt to be provided by TreeHouse. The notes are due in 2027 and carry an initial coupon of 10% for the first two years, escalating to 11% for the third year, 12% for the fourth year, and 13% thereafter. The notes are subject to restrictive covenants and are assignable by TreeHouse. The divested business is expected to generate 2022 net sales and adjusted EBITDA of approximately $1.6B and $70M, respectively. The categories to be divested include the following: pasta, pourable and spoonable dressing, preserves, red sauces, syrup, dry blends and baking, dry dinners, pie filling, pita chips and other sauces.The proceeds from the transaction will be used primarily to reduce debt and strengthen the balance sheet. Pro forma for the transaction and debt paydown, leverage is expected to be below 4.0x at year end. The transaction is expected to close in the fourth quarter of 2022 and is subject to customary closing conditions and regulatory approvals. Operating results for the categories to be divested will be reported in discontinued operations beginning in the third quarter of 2022. Evercore served as financial advisor to TreeHouse and Gibson Dunn served as legal advisor. Centerview provided a fairness opinion to the Board of Directors.

07:00 EDT Cardinal Health reiterates long-term targets - The company said, "The company reiterated its long-term targets of low to mid-single digit segment profit growth in the Pharmaceutical segment, mid to high-single digit segment profit growth in the Medical segment, and to average a double-digit combined Non-GAAP EPS growth and dividend yield. Additionally, the company is targeting Medical segment profit of at least $650 million by fiscal year 2025, based on its Medical Improvement Plan."

06:38 EDT Safehold, iStar enter strategic combination - Safehold (SAFE) and iStar (STAR) jointly announced that the two companies have entered into a definitive agreement for a tax-free, strategic combination. Under the terms of the transaction Safehold will internalize iStar's management team / intellectual property, replacing Safehold's external management structure. As part of the combination, Safehold will effectively assume iStar's $100M in L+150 trust preferred securities due 2035 and Safehold will effectively issue 1.2M new SAFE shares to iStar. The combined company will not be taking on other indebtedness or preferred equity from iStar. Ownership of New Safehold will remain largely proportionate to the ownership of Safehold immediately prior to consummating this transaction and New Safehold will continue to operate under the name Safehold Inc. Safehold shareholders are expected to own approximately 34% of New Safehold. iStar shareholders are expected to own approximately 37% of New Safehold directly and 14% indirectly as a result of the spin-off transaction discussed below. In conjunction with the transaction, iStar has agreed to sell SAFE shares representing 9% of SAFE shares outstanding to MSD Partners, L.P. and, separately, to settle its long-term management incentive plan obligations using its SAFE shares representing 6% of SAFE shares outstanding. Prior to the merger, iStar will spin off to iStar shareholders a new publicly traded entity that will own all of its remaining non-ground lease assets and $400M of its SAFE shares, enabling iStar shareholders to participate in the orderly monetization of these assets over time. SpinCo will be managed by New Safehold in exchange for a management fee. Concurrent with the closing of the transaction, MSD Partners will make strategic investments in both Safehold and Caret, establishing it as one of the largest shareholders of Safehold and the largest third-party investor in Caret: iStar will sell 5.4M shares of its SAFE holdings to MSD Partners for $200M, representing a price of $37 per share, and will use the proceeds to repay debt. Safehold will sell 100,000 units of Caret to MSD Partners for $20M, or $200 per unit, implying a total Caret valuation of $2B. The Caret units have no redemption options. iStar will contribute its remaining non-ground lease related legacy assets, the largest of which are Asbury Park and Magnolia Green, and approximately $400M of its SAFE stock to SpinCo. By retaining certain assets and pursuing their orderly monetization, SpinCo will enable iStar shareholders to capture their potential upside value. Additionally, SpinCo will be seeded with $50M of cash and capitalized with a $100M 8%, four-year term loan from New Safehold and up to $140M of bank debt from Morgan Stanley Bank, N.A. which will be secured by $400M shares of SAFE. iStar will distribute the equity interests in SpinCo to iStar shareholders on a one-for-one basis. New Safehold will enter into a management agreement with SpinCo, under which it will continue to operate and pursue the orderly monetization of SpinCo's assets. SpinCo will pay to New Safehold an annual management fee of $25M in year one, $15M in year two, $10M in year three and $5M in year four. This agreement will provide New Safehold time to transition its overhead and infrastructure costs. Prior to the closing of the transaction, iStar will undergo a reverse stock split to reduce the number of iStar shares outstanding to be equal to the number of SAFE shares owned by iStar immediately prior to the merger. At closing, the shares of SAFE owned by iStar will be retired and each share of SAFE not owned by iStar will be exchanged for one share of common stock of New Safehold. In connection with the transaction, iStar intends to retire its senior unsecured notes and cash out its preferred equity in the combination transaction using cash on hand and proceeds from asset sales and loan repayments. iStar will settle iPIP, its long-term incentive plan, using a portion of its shares of SAFE. In addition, Safehold will acquire iStar's interest in the Ground Lease Plus and Leasehold Loan funds in cash for $79M plus any future fundings prior to closing. Based on recent stock prices, book values and estimates on the pace of asset monetizations, each share of STAR would receive a combined implied value of approximately $18.39, comprised of interests in SpinCo with a book value of $6.48 per share and an estimated 0.27 shares of SAFE, which had a closing price of $43.45 on August 10, 2022. The transaction is expected to close in late Q4 or in Q1 2023, subject to satisfaction of closing conditions, including the approval of both iStar and Safehold shareholders and completion of the spin-off. The transaction was unanimously approved by the independent directors of iStar and Safehold based on the unanimous recommendations of special committees of the respective boards comprised solely of independent directors.

06:23 EDT AstraZeneca completes acquisition of TeneoTwo - AstraZeneca announced that it has "completed the acquisition of TeneoTwo, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.1 AstraZeneca will develop TNB-486 as a potential new medicine for B-cell haematologic malignancies. AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100M. Under the terms of the agreement, AstraZeneca will make additional contingent R&D-related milestone payments of up to $805M and additional contingent commercial-related milestone payments of up to $360M to TeneoTwo's former equity holders. This acquisition did not include the transfer of people or facilities."

06:08 EDT Six Flags drops 8% to $23.70 after Q2 results miss estimates

06:07 EDT Freyr Battery opens technology resources campus and business unit in Japan - Freyr Battery announced the establishment of a technology resources campus and business unit in Japan. The new business unit is the company's first physical location in Asia and will focus on efforts to facilitate and scale-up Freyr's testing and development of the 24M Technologies battery platform. Freyr's new facility will be located in Fukuoka where the testing equipment is currently being installed. Freyr's Japan technology resources unit will primarily be engaged in running electrochemical testing of various materials related to 24M's technology development, while also providing a platform for the recruitment and hiring of experienced battery engineering talent.

06:03 EDT Evelo Biosciences announces CEO succession plan - Evelo Biosciences announced the succession plan for Simba Gill, Ph.D., to transition from his roles as CEO and President to the role of Chair of the Board of Directors and return to Flagship Pioneering to help launch, grow, and guide bioplatform companies. The company's Board of Directors has retained Spencer Stuart, an executive search firm, to initiate a comprehensive search led by its current Chair, Lord Ara Darzi, to identify Dr. Gill's successor. Dr. Gill will continue to serve as CEO and President until his successor joins Evelo, at which time he will become Chair of the Board of Directors and Lord Darzi will become the Lead Independent Director of Evelo. In addition to serving as Evelo's Chair, Dr. Gill will return to Flagship Pioneering as an Executive Partner to engage in corporate development, platform strategy, and governance across several biotechnology companies in Flagship's portfolio.

05:17 EDT Roche receives FDA approval for Ventana MMR RxDx Panel label extension - Roche announced FDA approval of a label expansion for the Ventana MMR RxDx Panel. This approval advances the company's commitment to personalized healthcare through tests that determine which patients are most likely to respond to specific and targeted therapies.